American Society of Hematology

2017 ASH® Meeting on Hematologic Malignancies

September 08-09, 2017
Fairmont Chicago, Millennium Park, Chicago, IL

 Add to calendar 09/08/2017 07:00 AM09/09/2017 08:00 PMASH Meeting on Hematologic MalignanciesHear the top experts in hematologic malignancies discuss the latest developments in clinical care and find answers to your most challenging patient care questions.Fairmont Chicago, Millennium Park, Chicago, ILMM/DD/YYYY129600
      Get email updates

Registration for the 2017 meeting is now open.

Join us in Chicago for the 2017 ASH Meeting on Hematologic Malignancies and gain knowledge that can help you make an immediate impact on your practice. The meeting will feature the top experts in the field, comprehensive clinical content, the latest clinical research, and opportunities to interact with colleagues in an intimate, small-group setting with no competing sessions.

The program content will be structured as "How I Treat" presentations which will showcase each speaker's evidence-based treatment approaches, present cutting-edge scientific data that can be translated into new strategies for diagnosis and treatment, and address what to do in cases where there is no data. Experts will provide out-of-the-box treatment approaches, answer challenging patient care questions during topic-based panel discussions, and engage in stimulating conversations on specific disease topics during Lunch with the Experts sessions.

View Session Previews

Get a sneak peek at topics to be discussed during the 2017 meeting, including exciting updates in each of the core malignancies.

  • Leukemia
  • Lymphoma
  • Myelodysplastic syndromes
  • Myeloma
  • Myeloproliferative neoplasms

Key Date

Late/On-Site registration opensSeptember 7, 2017

Program Co-Chairs

Jonathan W. Friedberg, MD

Jonathan W. Friedberg, MD
University of Rochester

Ruben A. Mesa, MD

Ruben A. Mesa, MD
Mayo Clinic

Wendy Stock, MD

Wendy Stock, MD
University of Chicago

Program Planning Committee

  • Anjali Advani, MD, Cleveland Clinic
  • Jonathan W. Friedberg, MD, University of Rochester
  • John P. Leonard, MD, Weill Cornell Medical College
  • Ruben A. Mesa, MD, Mayo Clinic
  • Vincent Rajkumar, MD, Mayo Clinic
  • David Steensma, MD, Dana-Farber Cancer Institute
  • Wendy Stock, MD, University of Chicago

Corporate Support

Premier Commercial Support Level

  • AbbVie, Inc.
  • Amgen, Inc.
  • Astellas Pharma
  • AstraZeneca
  • Celgene Corporation
  • Incyte Corporation

Lead Commercial Support Level

  • Incyte Corporation
  • Jazz Pharmaceuticals
  • Novartis Pharmaceuticals, Inc.
  • Pharmacyclics
  • Takeda Oncology
  • Teva Oncology

General Support Level

  • Bristol-Myer Squibb
  • Seattle Genetics

Mobile App brought to you by: Otsuka America Pharmaceuticals, Inc.

2017 Meeting on Hematological Malignancies Exhibitors:

  • AbbVie, Inc.
  • Amgen, Inc.
  • Bayer HealthCare Pharmaceuticals
  • Celgene Corporation
  • Dana Farber Institute
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Incyte Corporation
  • Jazz Pharmaceuticals
  • Kite Pharma
  • Otsuka America Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Novartis Pharmaceuticals
  • Teva Oncology

For information about sponsoring and/or exhibiting at this meeting, contact Thelma Barnett at tbarnett@hematology.org

back to top